



THE 13th SUGIYAMA LABORATORY (RIKEN) OPEN SYMPOSIUM

“New challenges for in vitro and in vivo extrapolations with regard to DDI and clearance estimation; Albumin effect and critical scaling factors”

Date : 13:00 - 17:35, February 22nd, 2019

Venue : RIKEN Yokohama Main Office Building Hall

- 13:00-13:05 Opening remarks
Yuichi Sugiyama (Sugiyama Laboratory, RIKEN)
- 13:05-14:00 **【Plenary lecture】**
Visomedigib and Venetoclax: Approved Drugs with Unique Pharmacokinetic Properties
Cornelis “Marcel” Hop (Genentech inc.)
- 14:00-14:35 Development of Orthogonal Linear Separation Analysis (OLSA) to Decompose Pharmacological Effect and Extract Elementary Ones
Hiroyuki Kusuhara (The University of Tokyo / RIKEN)
- 14:35-15:05 PBPK model of rifampicin as a perpetrator integrating bottom-up and top-down approaches
Ryuta Asami (Ono Pharmaceutical Co., Ltd.)
- 15:05-15:25 Coffee break
- 15:25-15:55 Analysis of drug - drug interactions of pitavastatin and rosuvastatin with oral or intravenous administration of rifampicin using PBPK models.
Mayuko Miyagawa (Astellas Pharma Inc.)
- 15:55-16:25 Application of PBPK modeling to renal OCT2 and MATEs mediated DDIs: Predicting changes in renal clearance and blood AUC caused by the transporter inhibitors.
Kotaro Nishiyama (Nippon Boehringer Ingelheim Co., Ltd.)
- 16:25-16:55 In vitro and in vivo extrapolation of hepatic uptake clearances for drugs with high protein binding accounted for the "albumin mediated" hepatic uptake mechanism.
Seiji Miyauchi (Toho University / RIKEN)
- 16:55-17:35 General Discussion
Yuichi Sugiyama (Sugiyama Laboratory, RIKEN)
- 17:45-19:20 Banquet (Cafeteria at Yokohama RIKEN)